ARS PHARMACEUTICALS INC (SPRY) Stock Analyst Ratings
USA - NASDAQ:SPRY - US82835W1080 - Common Stock
8.96 USD
+0.34 (+3.94%)
8.92 USD
-0.04 (-0.45%)
ChartMill assigns a Buy % Consensus number of 88% to SPRY. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 31.96. This target is 256.7% above the current price.
SPRY was analyzed by 13 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about SPRY.
In the previous month the buy percentage consensus was at a similar level.
SPRY was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-04 | Roth Capital | Initiate | Buy |
| 2025-03-07 | ScotiaBank | Initiate | Sector Outperform |
| 2025-01-14 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-01-13 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-10-08 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-20 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-08-13 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2024-07-25 | Raymond James | Initiate | Outperform |
| 2024-03-11 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-03-05 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2023-11-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-09-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-09-20 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-08-14 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-06-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-05-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-10 | Wedbush | Reiterate | Outperform |
| 2023-01-31 | Wedbush | Initiate | Outperform |
| 2023-01-04 | William Blair | Initiate | Outperform |
| 2022-12-13 | SVB Leerink | Initiate | Outperform |
ARS PHARMACEUTICALS INC / SPRY FAQ
What do analysts expect the price target to be for ARS PHARMACEUTICALS INC (SPRY)?
13 analysts have analysed SPRY and the average price target is 31.96 USD. This implies a price increase of 256.7% is expected in the next year compared to the current price of 8.96.
What is the consensus rating for SPRY stock?
The consensus rating for ARS PHARMACEUTICALS INC (SPRY) is 87.6923 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for ARS PHARMACEUTICALS INC stock?
The number of analysts covering ARS PHARMACEUTICALS INC (SPRY) is 13.